Effects of policosanol on patients with ischemic stroke: A pilot open study

Journal of Medicinal Food

Volumn 9, Issue 3, 2006, Pages 378-385

  Ortega, L L ^a   Sanchez J ^a   Mas R ^b   Fernandez L ^b   Mendoza, S ^b   Gamez R ^b   Fernandez J C ^b   Illnait, J ^b   Alvarez, E ^b  

^a National Neurology Institute   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Antiplatelet drugs; Cholesterol lowering drugs; Policosanol; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLICOSANOL; TRIACYLGLYCEROL; VASODILATOR AGENT; VITAMIN; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INSOMNIA; IRRITABILITY; MALE; NEUROPROTECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SECONDARY PREVENTION; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; FOLLOW UP; MIDDLE AGED; PILOT STUDY; RECURRENT DISEASE;

AGED; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; FATTY ALCOHOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; VITAMINS;

EID: 33750617773     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.9.378     Document Type: Article

References (60)

1. Dirnagl U, Costantino I, Moskowitz MA: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
2. Bronner LL, Kunter DS, Mansom JE: Primary prevention of stroke. N Engl J Med 1995;333:1392-1400.
3. De Freitas GR, Bogousslavsky J: Primary stroke prevention. Eur J Neurol 2001;8:1-15.
4. Comision ECB MINSAP: Enfermedad Cerebrovascular (ECB) Actualizacion, MINSAP, Havana City, Cuba, 2003.
5. Bamford J: Clinical examination in diagnosis and subclassification of stroke. Lancet 1992;339:400-402.
6. Tran H, Anand S: Oral antiplatelel therapy in cerebrovascular disease, coronary arterial diseases and peripheral arterial disease. JAMA 2004;292:1867-1874.
7. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1428.
8. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
9. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148.
10. Laufs U, La Fata V, Plutzky J, Liao JK: Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
11. Henry RY, Kendall MJ: Does cholesterol lowering prevent stroke? J Clin Pharmacol Ther 1998;23:337-344.
12. Pearson TA: Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am J Cardiol 1998;82(Suppl):28S-30S.
13. Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-1463.
14. Di Mascio R, Marchioli R, Tognoni G: Cholesterol reduction and stroke occurrence: an overview of randomized controlled trials. Cerebrovasc Dis 2000;10:85-92.
15. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
16. Vauthey C, de Freitas GR, van Melle G, et al.: Better outcome after stroke with higher serum cholesterol levels. Neurology 2000;54:1944-1948.
17. Buchwald H, Campos CT, Boen JR, et al.: Disease-free interval after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol 1995;26:351-357.
18. Endres M, Laufs U, Huang Z, et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885.
19. Chen J, Zhang ZG, Li Y, et al.: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-751.
20. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30:1969-1973.
21. Mas R: Policosanol. Drugs Future 2000;25:569-586.
22. Mas R, Castaño G, Illnait J, et al.: Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998;65:439-447.
23. Castaño G, Mas R, Fernández L, et al.: Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;13:187-195.
24. Ortensi G, Gladstein H, Valli H, Tesone PA: A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997;58:390-401.
25. Castaño G, Mas R, Fernández L, et al.: Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with Type II hypercholesterolemia. Drugs Aging 2003;20:153-163.
26. Mas R, Castaño G, Fernández L, et al.: Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001;21:485-497.
27. Castaño G, Mas R, Fernández JC, et al.: Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A 2001;56:M186-M192.
28. Castaño G, Mas R, Fernández L, et al.: Effects of policosanol on older patients with hypertension and Type II hypercholesterolemia. Drugs R&D 2002;3:159-172.
29. Torres O, Agramonte AJ, Illnait J, et al.: Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-397.
30. Crespo N, Illnait J, Mas R, et al.: Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999;XIX:117-128.
31. Menéndez R, Fernández I, Del Río A, et al.: Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994;27:199-203.
32. Menéndez R, Amor A, Rodeiro I, et al.: Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001;32:8-12.
33. Menéndez R, Arruzazabala ML, Más R, et al.: Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1996;77:923-932.
34. Arruzazabala ML, Valdés S, Más R, et al.: Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996;34:181-185.
35. Carbajal D, Arruzazabala ML, Valdés S, Más R: Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61-64.
36. Castaño G, Más R, Arruzazabala ML, et al.: Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res 1999;XIX:105-116.
37. Menéndez R, Más R, Amor AM, et al.: Effects of policosanol treatment on the susceptibility of low-density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50:255-262.
38. Menéndez R, Más R, Amor A, et al.: Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. A randomised, double-blinded pilot study. Curr Ther Res 2000;61:609-620.
39. Castaño G, Más R, Fernández L, et al.: A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1998;50:123-130.
40. Castaño G, Mas R, Fernández L, et al.: A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-125.
41. Castaño G, Mas R, Fernández L, et al.: Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind pilot comparative study. Angiology 2003;54:25-38.
42. Castaño G, Más R, Gámez R, et al.: Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55:361-371.
43. Más R, Rivas P, Izquierdo JE, et al.: Pharmacoepidemiologic study of policosanol. Curr Ther Res 1999;60:458-467.
44. Mas R, Castaño G, Fernández JC, Illnait J, Fernández L, Alvarez E: Effects of policosanol (5-10 mg/day) on morbidity and mortality in older hypercholesterolemic patients [abstract]. J Am Coll Cardiol 2002;39(Suppl B):429B.
45. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
46. 2. Prostaglandins Leukot Essent Fatty Acids 1993;49:695-697.
47. Molina V, Arruzazabala ML, Carbajal D, et al.: Effect of policosanol on cerebral ischemia in Mongolian gerbils. Braz J Med Biol Res 1999;32:1269-1276.
48. Fernández L, Más R, Illnait J, Fernández JC: Policosanol: results of a postmarketing surveillance control on 27 879 cases. Curr Ther Res 1998;59:717-722.
49. Fernández S, Mas R, Gamez R, et al.: A pharmacological surveillance of policosanol tolerability in the elderly. Am J Geriatr Pharmacother 2004,2:219-229.
50. Cote R, Battista RN, Wolfson C, Boucher J, Adam J, Hachinski VCC: The Canadian Neurological Scale. Validation and reliability assessment. Neurology 1989;39:638-643.
51. Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
52. O'Brien PC, Shampo MA: Statistical considerations for performing multiple tests in a single experiment. Comparing two therapies with respect to several endpoints. Mayo Clin Proc 1988;63:1140-1143.
53. Yoon SS, Dambrosia J, Chalela J: Rising statin use and effect on ischemic stroke outcome. BMC Med 2004;2:1741-1747.
54. Cote R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C: The Canadian Neurological Scale. A preliminary study in acute stroke. Stroke 1986;17:731-737.
55. Bushnell CD, Johnston DC, Goldstein LB: Retrospective assessment of initial stroke severity: comparison of the NIH Stroke Scale and the Canadian Neurological Scale. Stroke 2001;32:656-660.
56. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
57. Arruzazabala ML, Valdés S, Mas R, et al.: Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997;36:293-297.
58. Love S: Oxidative stress in brain ischemia. Brain Pathol 1999;9:119-131.
59. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D: Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev 2002;54:271-284.
60. Martínez-Vila E, Irimia P: Factores de riesgo del ictus. Anal Sistema Sanitario Navarra 2000; 23(Suppl 3):25-31.